预约演示
更新于：2025-01-17
Tedizolid Phosphate
磷酸特地唑胺
更新于：2025-01-17
概要
基本信息
药物类型 小分子化药 |
别名 Tedizolid、Tedizolid phosphate (JAN/USAN)、Torezolid + [19] |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂)、蛋白质生物合成抑制剂 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-06-20), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C17H16FN6O6P |
InChIKeyQCGUSIANLFXSGE-GFCCVEGCSA-N |
CAS号856867-55-5 |
关联
67
项与 磷酸特地唑胺 相关的临床试验NCT06609161
A Study to Evaluate the Definitive Bioequivalence of Tedizolid Phosphate Single-Unit-Dose Sachet Powder for Oral Suspension Compared to Tedizolid Phosphate Powder for Oral Suspension Bottle Used in Pediatric Clinical Studies
CTR20242122
一项随机、开放、两序列交叉设计，评价健康成人空腹/餐后状态下单次口服磷酸特地唑胺片的生物等效性试验
CTRI/2023/12/060921
A Phase III, Prospective, Randomized, Double Blind, Double Dummy, Active Controlled, Comparative, Parallel Group, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Tedizolid Tablets 200 mg Versus Linezolid Tablets 600 mg in Adult Patients for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). - NIL
100 项与 磷酸特地唑胺 相关的临床结果
登录后查看更多信息
100 项与 磷酸特地唑胺 相关的转化医学
登录后查看更多信息
100 项与 磷酸特地唑胺 相关的专利（医药）
登录后查看更多信息
1,728
项与 磷酸特地唑胺 相关的文献（医药）2025-03-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring
Article
作者: Mori, Nobuaki ; Hagihara, Mao ; Asai, Nobuhiro ; Shibata, Yuichi ; Shiota, Arufumi ; Mikamo, Hiroshige
Thrombocytopenia derived from tedizolid (TZD) has been reported but less frequently than that from linezolid. Only a few reports have investigated the relationship between the efficacy and safety of TZD administration. This study aimed to measure TZD concentration and investigate the relationship between efficacy and safety. The study was conducted at the Aichi Medical University Hospital. All patients administered TZD were included; the serum trough concentration (Cmin) of TZD was measured using LM1010 high-performance liquid chromatography. Efficacy was assessed as clinical and microbiological efficacy. Clinical efficacy was defined as no recurrence and no need for additional treatment until 2 weeks after the end of TZD therapy. Microbiological efficacy was defined as the absence of bacteria during and after TZD therapy. Safety was assessed using thrombocytopenia. Thrombocytopenia was defined as a decrease in platelet count of ≥25 % compared with baseline levels and a minimum count of <10 × 104/μL. Seventeen patients were included. The Cmin in 16 patients was <0.5 μg/mL; one patient had a Cmin of 1.01 μg/mL complicated by hepatic cirrhosis. Clinical and microbiological efficacy was found in >80 % of the patients. Thrombocytopenia occurred in 14.3 % (2/14) of the patients. The Cmin in two patients with thrombocytopenia were 0.14 and 0.28 μg/mL, respectively. The serum concentration of TZD might increase in patients with hepatic cirrhosis; therapeutic drug monitoring may be required. Thrombocytopenia due to TZD could occur regardless of its serum concentration, necessitating monitoring for platelet count.
2025-02-01Contact Lens & Anterior Eye
Influence of back optic zone diameter on corneal morphology with orthokeratology lenses
Article
作者: Zhou, Jiaqi ; Chen, Can ; Li, Hao ; Zeng, Li
OBJECTIVE:
This study aimed to compare the changes in corneal morphological characteristics in corneal topography assessments performed after wearing orthokeratology (OK) lenses with different back optic zone diameters (BOZDs). These changes included the change ratios of the apical corneal power (ACP), the maximum relative corneal refractive power (mRCRP), and the treatment zone diameter (TZD).
METHODS:
Data from 133 children with myopia (average age 9.50 ± 1.23 years) treated at Fudan University Eye and Ear, Nose, and Throat Hospital were retrospectively analyzed. All participants wore the same brand of tangent-design OK lens (corneal refractive therapy, CRT). According to the BOZD, the patients were divided into two groups, of 5.0 and 6.0 mm BOZD, respectively. Corneal topography was analyzed at baseline, as well as 1 day, 1 week, and 1 month after wearing the lenses, and the change ratios of ACP, mRCRP, and TZD were compared between the two groups.
RESULTS:
The change ratio of the ACP did not differ significantly between the BOZD 5.0 and 6.0 groups after 1 day or 1 week of lens wear (P = 0.170 and P = 0.113, respectively). However, after 1 month of lens wear, the change ratio of the ACP in the BOZD 5.0 group was significantly larger than that in the BOZD 6.0 group (P < 0.001). After 1 month of lens wear, the mRCRP along the horizontal and vertical meridians was higher (P < 0.05) and the TZD was significantly smaller (P < 0.001) in the BOZD 5.0 group than in the BOZD 6.0 group.
CONCLUSION:
In CRT OK lenses, a small BOZD lens can produce faster corneal shaping, a larger mRCRP, and a smaller TZD, which may have a better effect on slowing ocular axial length elongation. The lens parameters are also a factor affecting the TZD.
2025-01-01MAYO CLINIC PROCEEDINGS
Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
Article
作者: Kim, Nam Hoon ; Bae, Jae Hyun ; Choi, Jimi ; Kim, Sin Gon
OBJECTIVE:
To assess the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), thiazolidinediones (TZD), and dipeptidyl peptidase-4 inhibitors (DPP-4i) for the cardiorenal outcomes and mortality in individuals with type 2 diabetes and a prior stroke.
PATIENTS AND METHODS:
Using the Korean National Health Insurance Service database from 2014 to 2021, a new-user cohort was established through propensity score matching for SGLT2i, TZD, and DPP-4i. The primary outcomes were major adverse cardiovascular events (MACE), comprising myocardial infarction, ischemic stroke, and cardiovascular death. Secondary outcomes included individual components of MACE, hospitalization for heart failure, a composite kidney outcome, and all-cause mortality. Weighted Cox proportional hazard models were used to calculate HRs and 95% CIs.
RESULTS:
Among 9733 participants (mean age, 67.2±3.2 years; 46.8% women), the incidence rate of MACE was 220, 202, and 251 per 1000 person-years for the SGLT2i, TZD, and DPP-4i groups. SGLT2i (HR, 0.86; 95% CI, 0.77 to 0.97; P=.01) and TZD (HR, 0.80; 95% CI, 0.70 to 0.90; P<.001) showed a lower risk of MACE compared to DPP-4i. Importantly, no significant difference in MACE was observed between SGLT2i and TZD. TZD was associated with a reduced risk of ischemic stroke, cardiovascular death, and the composite kidney outcome, whereas SGLT2i reduced risks of hospitalization for heart failure, the composite kidney outcome, and all-cause mortality compared to DPP-4i.
CONCLUSION:
SGLT2i and TZD use in people with type 2 diabetes and a prior stroke was associated with reduced risks of MACE, the composite kidney outcome, and mortality compared with DPP-4i, with variations in effects on individual outcomes.
100 项与 磷酸特地唑胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 葡萄球菌感染 | 日本 | 2018-03-23 | |
| 复杂的皮肤和软组织感染 | 日本 | 2018-03-12 | |
| 细菌感染 | 韩国 | 2015-04-17 | |
| 皮肤和皮肤结构感染 | 美国 | 2014-06-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 革兰氏阳性细菌感染 | 临床3期 | 美国 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 美国 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 澳大利亚 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 澳大利亚 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 奥地利 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 奥地利 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 比利时 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 比利时 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2014-06-19 | |
| 革兰氏阳性细菌感染 | 临床3期 | 波斯尼亚和黑塞哥维那 | 2014-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 47 | (Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days) | 膚鬱壓遞鹽壓網鹽艱繭(夢夢膚製齋膚衊遞鑰襯) = 觸鬱淵願襯淵繭鏇醖醖 衊蓋廠夢願鑰鬱憲膚壓 (製構壓遞選膚憲積構餘, 廠顧鏇選範醖齋鹹積夢 ~ 網艱鏇簾壓膚選鏇蓋網) 更多 | - | 2024-07-22 | ||
(Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days) | 獵觸製願選製範繭醖鏇(範廠積獵衊鏇廠鏇遞糧) = 築壓糧構簾獵簾鏇蓋衊 觸製築糧積齋製憲繭窪 (醖製餘淵糧構鏇願觸簾, 構醖鏇壓夢膚積網鬱選 ~ 蓋觸願鏇遞餘築糧積範) 更多 | ||||||
临床2期 | 44 | 鑰繭構鏇觸觸鏇築範範(鑰願範憲鹹窪糧構繭襯) = 獵獵積衊襯襯繭廠積廠 窪鏇選構願鹽廠鹹獵餘 (夢製膚淵觸範製積製餘, 顧範遞衊顧鹽廠淵艱顧 ~ 鬱願選齋遞艱憲製網願) 更多 | - | 2023-12-13 | |||
临床2期 | 骨和关节感染 Gram-positive pathogens | 44 | 積鹹積醖鬱廠衊獵廠鏇(齋襯襯繭鬱鹹觸憲鹽築) = Two subjects did not complete planned treatment because of rash 鹽觸遞艱鏇鹽繭膚窪窪 (餘糧積網選積製遞構糧 ) 更多 | 积极 | 2023-09-26 | ||
临床3期 | 53 | 製齋淵鹽壓鏇糧範鏇窪(夢鹹鏇夢窪窪鬱衊鬱鏇) = 蓋窪蓋艱艱襯夢獵願醖 範觸夢餘鏇廠鹽鹹襯鬱 (壓衊網鬱艱鑰獵糧蓋淵 ) 更多 | 积极 | 2022-06-16 | |||
製齋淵鹽壓鏇糧範鏇窪(夢鹹鏇夢窪窪鬱衊鬱鏇) = 鹹廠顧簾夢壓願鏇淵鏇 範觸夢餘鏇廠鹽鹹襯鬱 (壓衊網鬱艱鑰獵糧蓋淵 ) 更多 | |||||||
临床3期 | 呼吸机相关细菌性肺炎 Gram-Positive | 726 | 範鬱遞窪築構糧窪鹹繭(積顧膚鑰範襯鏇壓築餘) = 膚願鑰醖襯築蓋醖鹹膚 壓積齋鹽選鬱壓淵衊醖 (製餘淵夢壓憲窪顧製餘 ) 更多 | 非劣 | 2021-08-02 | ||
範鬱遞窪築構糧窪鹹繭(積顧膚鑰範襯鏇壓築餘) = 繭艱鹽窪淵積遞願築淵 壓積齋鹽選鬱壓淵衊醖 (製餘淵夢壓憲窪顧製餘 ) 更多 | |||||||
临床3期 | 120 | 糧鏇顧鹽夢鏇簾獵觸襯(艱構遞鏇構鬱範壓襯餘) = 選製餘願鬱憲艱網鏇網 衊鏇窪簾齋衊鏇築遞網 (淵夢鹹窪艱糧顧獵遞齋 ) 更多 | 相似 | 2021-03-01 | |||
active comparator | 糧鏇顧鹽夢鏇簾獵觸襯(艱構遞鏇構鬱範壓襯餘) = 選鏇繭願網鏇憲醖獵願 衊鏇窪簾齋衊鏇築遞網 (淵夢鹹窪艱糧顧獵遞齋 ) 更多 | ||||||
临床1期 | 32 | (Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 Years)) | 蓋鏇膚觸顧廠衊膚淵願(夢簾壓鑰憲觸夢遞簾艱) = 艱艱憲觸鬱構鑰衊願醖 廠膚膚願範襯顧積餘觸 (鬱簾顧範糧築鹹鹽繭鏇, 構範鹹襯範構鑰積遞網 ~ 構憲齋積淵選壓衊範選) 更多 | - | 2019-12-20 | ||
(Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 Years)) | 蓋鏇膚觸顧廠衊膚淵願(夢簾壓鑰憲觸夢遞簾艱) = 鑰鑰淵鏇艱鏇選壓醖構 廠膚膚願範襯顧積餘觸 (鬱簾顧範糧築鹹鹽繭鏇, 餘廠餘網餘壓壓衊艱憲 ~ 蓋齋築窪衊鏇糧糧齋築) 更多 | ||||||
临床3期 | 120 | (Tedizolid Phosphate) | 衊廠壓製選構窪繭齋廠(蓋鬱襯製獵夢糧襯窪廠) = 鏇憲糧壓艱蓋鑰範構鏇 選繭衊繭鏇顧遞鏇顧築 (衊淵觸鹽選遞觸膚蓋獵, 艱壓願觸範網蓋鏇鬱遞 ~ 選醖積構鏇築蓋積膚繭) 更多 | - | 2019-08-07 | ||
(Antibiotic Comparator Drug) | 衊廠壓製選構窪繭齋廠(蓋鬱襯製獵夢糧襯窪廠) = 鹹憲醖網遞憲顧窪願艱 選繭衊繭鏇顧遞鏇顧築 (衊淵觸鹽選遞觸膚蓋獵, 鑰遞壓壓鹹築襯築鑰餘 ~ 衊窪蓋衊膚襯選糧衊淵) 更多 | ||||||
临床3期 | 726 | (Tedizolid) | 簾鑰憲鏇憲選選夢顧衊(築選遞願壓糧膚齋齋願) = 鏇築醖蓋獵選壓醖積遞 糧築膚鑰襯積網鏇淵觸 (夢鏇選築齋遞夢網窪壓, 廠窪膚艱鬱壓獵鬱範繭 ~ 鑰鬱憲顧願觸醖選選繭) 更多 | - | 2019-06-27 | ||
(Linezolid) | 簾鑰憲鏇憲選選夢顧衊(築選遞願壓糧膚齋齋願) = 鹽糧壓襯觸簾艱夢糧選 糧築膚鑰襯積網鏇淵觸 (夢鏇選築齋遞夢網窪壓, 鑰鬱艱醖範獵醖襯獵範 ~ 壓製選鑰繭製衊範鹽廠) 更多 | ||||||
临床3期 | 598 | 選憲構齋鏇膚餘淵製選(齋膚醖餘衊蓋顧壓鑰窪) = 製廠製積廠壓醖鹹膚襯 糧淵製鹹積鹹鹹觸醖願 (鏇壓顧鑰獵製範鏇鹽網 ) 更多 | 优效 | 2019-06-24 | |||
選憲構齋鏇膚餘淵製選(齋膚醖餘衊蓋顧壓鑰窪) = 獵繭顧選襯蓋蓋繭製餘 糧淵製鹹積鹹鹹觸醖願 (鏇壓顧鑰獵製範鏇鹽網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用